The Department for Business and Trade ("DBT") are bringing an exciting opportunity for a Senior Product Manager to champion the delivery and continuous improvement of products and define, own, and solve problems that enable value.
Join a team at the heart of the global economy!
£53,560 to £65,300 including allowances plus 27% pension contribution and other excellent Civil Service benefits.
Working from your home-office you will be responsible for identifying leads and securing laboratory services in this sector.
Our client is an international contract testing organisation that provide specialised solutions for customers across multiple industries such as food, environmental, pharma, medical devices, forensics etc.
In this position you will be tasked with establishing our client's footprint in the pharmaceutical sector across the UK territory.
Posted by Wallace Hind Selection • £50K/yr to £65K/yr
General
Use your knowledge of, and experience in industrial OEM and MRO consumables and components logistics and supply chains in this Business Development Manager/Account Manager role.
This is an exciting opportunity in a multinational group with very good career prospects, which will play a pivotal role in their new business development and future success.
Posted by Harnham - Data & Analytics Recruitment • £60K/yr to £75K/yr
General
Senior Research Data Scientist
Manchester (Hybrid, 3 days per week)
Company
This company is a global leader in Customer Data Science, who work across customer analytics and loyalty working as a consultancy services giving you're the opportunity to work with market leading business & retailers!
Position Overview: Reed are proud to be working a leading institution in clinical research in their search for junior doctors to assist in a clinical trial.
Participants take part remotely (by completing questionnaires on their own device or during telephone interviews with research nurses) and study treatment is sent to their homes by post.
The trial seeks to investigate the effect of oral semaglutide vs. placebo on cardiovascular outcomes in up to 20,000 participants with type 2 diabetes.